Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Piraeus – page 9

129 clinical trials in Piraeus, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Piraeus at a glance
129
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

129 trials in Piraeus

Open in trial search

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Study to Compare Fianlimab and Cemiplimab Combination with Cemiplimab Alone for Adults with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of Alectinib and Platinum-Based Chemotherapy for Patients with Resected Stage Ib to IIIa ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Brodalumab
  • Sponsor:Leo Pharma A/S

Breast cancer+3

Not recruiting

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Genentech Inc.

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Hypertension

Not recruiting

Study on the Effects of Amlodipine and Irbesartan in Patients with High Blood Pressure

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Amlodipine
  • Sponsor:Win Medica Pharmaceutical S.A.

Other cities in Greece

The busiest research cities in the country

All 50 cities in Greece

Clinical research in Piraeus

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on various cancer treatments, particularly in non-small cell lung cancer and novel therapeutic combinations. Studies include investigations of targeted therapies and immunotherapy approaches.

  • Lung Cancer Therapies
  • Melanoma Treatments
  • Renal Cell Carcinoma

Innovative research combining standard treatments with new therapeutic agents to improve patient outcomes.

02 Cardiovascular Studies

Research initiatives targeting heart failure prevention and stroke prevention in patients with atrial fibrillation. Studies evaluate new therapeutic approaches for managing cardiovascular risks.

  • Heart Failure Prevention
  • Stroke Prevention
  • Hypertension Management

Trials focusing on both preventive measures and treatment of established cardiovascular conditions.

03 Hematology Research

Clinical investigations in multiple myeloma and related blood disorders, exploring combination therapies and novel treatment approaches for patients with various blood-related conditions.

  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Blood Disorders

Studies examining innovative therapeutic combinations for improved patient outcomes.

04 Inflammatory Conditions

Research focusing on treating Crohn's Disease and other inflammatory conditions, evaluating new therapeutic options and combination treatments for better disease management.

  • Gastrointestinal Disorders
  • Autoimmune Conditions
  • Novel Therapies

Studies aimed at improving treatment outcomes in chronic inflammatory diseases.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.